United States· US:51862-095_3dfeb589-b234-6c61-e063-6294a90a1deb
DISOPYRAMIDE PHOSPHATE
A disopyramide product containing disopyramide phosphate, registered in United States by Mayne Pharma Commercial LLC. The same ATC class is registered in 9 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Disopyramide is registered in 9 of 19 countries.
Countries holding a registration under ATC C01BA03 (disopyramide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Disopyramide · ATC C01BA03
9 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Japan
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DISOPYRAMIDE PHOSPHATE
- Manufacturer
- Mayne Pharma Commercial LLC
- Country
- United States (US)
- ATC code
- C01BA03
- ATC class
- Disopyramide
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 12, 2026
Packs & prices · 2
- ndc1151862-095-01
- ndc115186209501100 CAPSULE in 1 BOTTLE (51862-095-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
341 interactions on record for disopyramide.
Graded by severity as the source publishes them — 138 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Disopyramide · interactions on record
341 records
- 138 severe
- 182 moderate
- 10 minor
- 11 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Disopyramide in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomDisopyramide 100mg capsulesMedihealth (Northern) Ltd
- SpainDICORYNAN 100 mg CAPSULAS DURASCheplapharm Arzneimittel Gmbh
- BelgiumRythmodan 100 mgCheplapharm Arzneimittel
- FranceRYTHMODAN 100 mg, géluleCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
- FinlandDurbissanofi-Aventis Oy
- CanadaRYTHMODANCHEPLAPHARM ARZNEIMITTEL GMBH
- NorwayRitmodan RetardSanofi
- ItalyRITMODAN RETARD*20 cpr 250 mgCHEPLAPHARM ARZNEIMITTEL GMBH
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Belgium · Rythmodan, Rythmodan Long Action
- Spain · Dicorynan
- France · Isorythm L.P., Rythmodan
- United Kingdom (Northern Ireland) · Disopyramide Neon, Disopyramide Neon Healthcare
- Italy · Ritmodan, Ritmodan Retard
- Luxembourg · Rythmodan, Rythmodan Long Action
- Netherlands · Ritmoforine Retard
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2f58781-5efc-4b77-be4a-3deb7973a5f0 GET /v1/drugs/e2f58781-5efc-4b77-be4a-3deb7973a5f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "DISOPYRAMIDE PHOSPHATE",
"productndc": "51862-095",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA070173",
"marketing_category": "ANDA"
}See everything about disopyramide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.